Shenqi Fuzheng Injection Reverses Cisplatin Resistance through Mitofusin-2-Mediated Cell Cycle Arrest and Apoptosis in A549/DDP Cells

Figure 7

Mfn2 is involved in reversing cell cycle inhibition and cell apoptosis upon cotreatment with cisplatin and SFI. (a, b, and c) A549/DDP cells were pretreated with various concentrations (2, 3.78, and 35.18 mg/mL) of SFI for 2 hours and then exposed to cisplatin (40 μg/mL) for another 24 hours. After drug intervention, (a) cell lysates were prepared and subjected to immunoblotting with antibodies to Mfn2 and β-actin; (b) cells were incubated with JC-1 and analyzed by flow cytometry; and (c) cells were labeled with DCFH-DA and the fluorescence intensity of the oxidized product DCF in individual cells was detected by flow cytometry and fluorescence microscopy. (d, e, and f) A549/DDP cells were pretreated with or without 2.5 mM of NAC, followed by cisplatin (40 μg/mL) and SFI (35.18 mg/mL) cotreatment. After drug intervention, (d) cell lysates were prepared and subjected to immunoblotting with antibodies to Mfn2 and β-actin; (e) cell cycle distribution by PI staining and DNA contents were determined by flow cytometry; and (f) apoptosis was determined by Annexin V-FITC/PI staining and analyzed by flow cytometry.

(a)

(b)

(c)

(d)

(e)

(f)